News und Analysen
If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy
If you have been or are thinking about getting into AbbVie (NYSE: ABBV), there is still time to do so. The AbbVie stock price is in a sustained uptrend
EQS-Adhoc: Merck KGaA: Merck bestätigt weit fortgeschrittene Gespräche mit SpringWorks Therapeutics, Inc. zu möglicher Übernahme
BioNTech präsentiert auf der AACR-Jahrestagung 2025 klinische und präklinische Daten zu mRNA- und Immunonkologie-Fokus-Programmen
MAINZ, Deutschland, 24. April 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, „BioNTech“ oder „das Unternehmen“) wird auf der diesjährigen Jahrestagung der American Association for Cancer
Thermo Fisher Stock: Q1 Beat Overshadowed by Outlook Cut
Thermo Fisher Scientific posted strong first-quarter 2025 results, exceeding analyst expectations with earnings per share of $5.15 against predicted $5.10, and revenue of $10.36 billion versus
Starke Verkäufe von Cresemba® (Isavuconazol) in Japan lösen zweite Umsatzmeilensteinzahlung von Asahi Kasei Pharma an Basilea aus
Allschwil, 24. April 2025
Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel, Patienten zu helfen, die an
![[Ad hoc-Mitteilung gemäss Art. 53 KR] Roche setzt Wachstumskurs mit Umsatzplus von 6% (CER) im ersten Quartal 2025 fort](https://www.sharewise.com/assets/news/news3-b9ff6b4b3cbc4e41e2e273fc3862605edd2b83b4887b24f79ecfa3288a635507.png)
[Ad hoc-Mitteilung gemäss Art. 53 KR] Roche setzt Wachstumskurs mit Umsatzplus von 6% (CER) im ersten Quartal 2025 fort
- Konzernverkäufe stiegen um 6%1 zu konstanten Wechselkursen (CER; 7% in CHF) dank hoher Nachfrage nach innovativen Medikamenten und diagnostischen Lösungen.
- Verkäufe der Division Pharma wuchsen um
3 Stocks to Buy Now for Tariff Immunity
There’s a new commodity in the financial markets today, and that’s any stock (or business, for that matter) that carries a certain level of immunity to the recent trade tariffs rolled out by
Eli Lilly Nails Oral GLP-1 Trial—Here’s What It Means for LLY
The world’s largest pharmaceutical stock, Eli Lilly and Company (NYSE: LLY), is back in the green in 2025 as of the Apr. 21 close. Shares were down
Medtronic: A Dividend Aristocrat With Stability and Innovation
Investors increasingly seek stable and resilient investments in today's volatile and economically uncertain market. Consequently, it is crucial to
UnitedHealth Group: Pariah to Pole Position to Buy the Dip Levels
UnitedHealth Group Inc. (NYSE: UNH) is a bellwether for the health insurance industry. The company symbolized the flaws in managed care organizations
BioNTech veröffentlicht am 5. Mai 2025 Ergebnisse für das erste Quartal 2025 und informiert über operativen Fortschritt
MAINZ, Deutschland, 22. April 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, „BioNTech“ oder „das Unternehmen“) wird am Montag, den 5. Mai 2025, die Ergebnisse für das erste Quartal 2025
Unitedhealth Stock: Dramatic 20% Plunge Shocks Market
UnitedHealth Group shares experienced a catastrophic drop on Thursday, plummeting by over 20% following disappointing first-quarter results. The healthcare giant saw its stock trading as low as
Tariff-Resistant Abbott Laboratories on Track for New Highs
Abbott Laboratories (NYSE: ABT) is not immune to the impact of tariffs on its medical device business. However, the company’s diversified business is tariff-resistant, and moves are being made to
Johnson & Johnson Earnings Were More Good Than Bad—Time to Buy?
Johnson & Johnson (NYSE: JNJ) delivered a solid earnings report on April 15.
[content-module:CompanyOverview|NYSE:JNJ]On the one hand, the company beat on the top and bottom lines and offered
2 Healthcare Stocks to Buy and 1 to Approach With Caution
While healthcare stocks have underperformed broader equities in recent years, there are still highly attractive companies in the sector worth consideration. However, other fairly popular healthcare
What to Look for Before Buying a Pharma Stock
There are many criteria for evaluating a pharmaceutical stock, but one of the easiest to start with is the drug pipeline. You can do so by looking at quarterly reports or listening to earnings
Could AbbVie Crash Lilly's Weight‑Loss Party?
AbbVie's (NYSE: ABBV) most important therapeutic area has historically been immunology, where it has marketed billion-dollar drugs like Humira, which was once the world's best-selling medicine. The
S&P 500 Index Dividend Yields Are Teasing All-Time Lows. Here Are 3 Dividend Darlings That Crush This Trend.
Don't look now, but the S&P 500 index is becoming something of a desert for income investors. As reported recently by Yahoo! Finance, the average dividend yield of all 500 titles has shriveled to
The Great Rotation: Buy This Sector Before It Comes Back in Style
Most people hate health insurance. And yet, historically, it has been one of the most profitable sectors to invest in, thanks to the durable nature of industry spending and the overall growth in
Market Crash: This Dividend Stock Becomes a No-Brainer Buy at a Discount
I feel like it's time for a confession, so here it is: Not every stock that I love is a winner right now. But I tend to fall hard for companies that I know are solid and will rebound when the time
Better Buy Right Now: Johnson & Johnson Vs. Pfizer
As large tech companies struggled this year, investors have had a chance to reevaluate their portfolios and identify where they may be underexposed to certain sectors.
One of those sectors may be
Massive News for UnitedHealth Stock Investors
UnitedHealth (NYSE: UNH) stock investors are happy to see these latest developments.
*Stock prices used were the afternoon prices of April 8, 2026. The video was published on April 10, 2026.
A Healthcare Stock With a 6%-Plus Yield: Is the Dividend Safe?
Although high dividend yields are attractive to income seekers, they can sometimes signal that the dividend is unsustainable and a payout cut is on the way. Is that where we are headed with Pfizer
Could Buying This Dividend Pharma Stock Today Set You Up for Life?
If you are a retiree looking to supplement your Social Security checks with income you derive from dividend stocks, you'll want to get to know Johnson & Johnson (NYSE: JNJ). It has a dividend record
Why Terns Pharmaceuticals Stock Rocked the Market in March
Terns Pharmaceuticals (NASDAQ: TERN) had a more memorable March than a great many other companies on U.S. stock exchanges. That's largely because it agreed to be bought out by a much larger peer